Efficacy and safety of simeprevir/pegylated interferon/ribavirin for patients with HCV

Efficacy and safety of simeprevir/pegylated interferon/ribavirin for patients with HCV - SMV RCT study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012384

Enrollment

400

Registered

2013-12-01

Start date

2013-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic liver disorder infected with hepatitis C virus

Interventions

Simeprevir, RIbavirin, Pegylated interferon alpha 2a Simeprevir, RIbavirin, Pegylated interferon alpha 2b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with more than 5 Log copies/ml of genotype 1 HCV

Exclusion criteria

Exclusion criteria: pregnant woman Uncontrolled heart diseases Chronic renal failure Depression Hepatic cirrhosis Hepatocellular carcinoma Autoimmune hepatitis Drug allergy for ribavirin, interferon, and simeprevir

Design outcomes

Primary

Measure	Time frame
Eradication of hepatitis C virus	—

Countries

Japan

Contacts

Public ContactAkihiro Tamori

Osaka City University Graduate School of Medicine Department of Hepatology

atamori@med.osaka-cu.ac.jp06-6645-3435

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026